Research progress on antimalarial combination therapy based on artemisinin-based compounds
- VernacularTitle:以青蒿素类化合物为基础的抗疟联合疗法研究进展
- Author:
Yingying YAN
1
,
2
;
Huimin ZHANG
2
;
Xiaojing LI
2
;
Zongtong YANG
2
;
Zaiyun SUI
2
Author Information
1. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China
2. Shandong Academy of Chinese Medicine，Jinan 250014，China
- Publication Type:Journal Article
- Keywords:
artemisinin;
artemisinin-based compounds;
combination therapy;
malaria
- From:
China Pharmacy
2022;33(15):1905-1910
- CountryChina
- Language:Chinese
-
Abstract:
Malaria is a serio us and life-threatening infectious disease that has a profound impact on human life. Artemisinin is still the first-line drug for clinical antimalarial treatment recommended by the World Health Organization. The antimalarial activity of artemisinin is mainly reflected in the peroxide bridge structure. Artemisinin-based combination therapy （ACT）is the first-line treatment for malaria in many countries. ACT mainly include artemether-lumefantrine ，artesunate-amodiaquine and dihydroartemisinin- piperaquine，etc. Compared with artemisinin monotherapy ，ACT has the advantages of shortening the length of hospital stay ， speeding up parasite clearance ，and saving economic costs ，etc. However ，there are still problems such as drug resistance. This article reviews the application status ，advantages and disadvantages of ACT at home and abroad in recent years ，in order to provide ideas for the subsequent screening of long-acting adjuvant antimalarial drugs in ACT and to solve the problem of drug resistance.
